Thelansis’s “Chronic Hand Eczema (CHE) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Chronic hand eczema (CHE) is a relapsing inflammatory disorder of the hands and wrists that persists for over three months or recurs at least twice yearly. Causes include irritant or allergic contact exposure, atopic susceptibility, or overlapping factors. Erythema, scaling, vesicles, hyperkeratosis and painful fissures can impair grip and work. Diagnosis is clinical; exposure history and patch testing help identify contact allergy. Management combines trigger reduction and emollients with topical corticosteroids for flares; phototherapy or systemic treatment may be considered for severe disease. Alitretinoin is used in some regions for severe refractory cases. Delgocitinib cream, a topical JAK inhibitor, is approved in the US and EU for adults with moderate-to-severe CHE inadequately controlled by, or unsuitable for, topical corticosteroids. Relapse and occupational impact remain major challenges. Long-term control depends on reducing wet work and relevant exposures.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Chronic Hand Eczema (CHE) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Chronic Hand Eczema (CHE) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.